Research programme: HIV integrase inhibitors - Merck

Drug Profile

Research programme: HIV integrase inhibitors - Merck

Alternative Names: L-870812; L-900564; MK-2048

Latest Information Update: 29 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Naphthyridines; Pyrimidinones
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for HIV infections in USA (PO)
  • 10 Apr 2008 Interim pharmacokinetics and pharmacodynamics data from a preclinical study in HIV Infections presented at the the 235th American Chemical Society National Meeting (235th-ACS-2008)
  • 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top